Pricing Log in Create free account
Saturday 17 October 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Zoetis Inc. (ZTS) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, Zoetis Inc. (ZTS) trades at a price to free cash flow of 14.2×. Over the past ten years it has ranged from 12.4× (October 2026) to 69.1× (August 2023); the current reading is higher than 3% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 16.1× and below the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 24.4× (24.11%)
FY2024 32.2× (42.42%)
FY2023 55.9× 7.78%
FY2022 51.9× (22.09%)
FY2021 66.6× 43.37%
FY2020 46.5× (0.45%)
FY2019 46.7× 70.31%
FY2018 27.4× (9.68%)
FY2017 30.3× (32.96%)
FY2016 45.3× (16.47%)

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 12.9× (41.93%)
Mar 2026 22.2× (9.14%)
Dec 2025 24.4× (15.53%)
Sep 2025 28.9× (5.47%)
42 more quarters

Against its own ten years

Low 12.4× High 69.1×
Ten-year median 45.2×
Current reading's percentile 3

Price to free cash flow against peers

Company Price to free cash flow
TAK Takeda Pharmaceutical Co. compare 8.4×
HLN Haleon PLC Sponsored ADR compare 10.2×
VTRS Viatris Inc. compare 11.5×
ZTS Zoetis Inc. 14.2×
NBIX Neurocrine Biosciences, Inc. compare 15.7×
UTHR United Therapeutics Corporation compare 20.9×
ELAN Elanco Animal Health Incorporated compare 33.0×
TEVA Teva Pharmaceutical Industries Ltd. compare 34.5×
RDY Dr. Reddy's Laboratories Ltd compare 73.5×
Drug Manufacturers Specialty & Generic industry median 16.1×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on ZTS